1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 11,140 | 11,220 | 07:49 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| DEVYSER DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| Di | Devyser Diagnostics AB: Devyser CFTR achieves IVDR compliance, strengthening clinical confidence in cystic fibrosis diagnostics | 168 | GlobeNewswire (Europe) | Devyser, a pioneer in advanced genetic testing solutions, is pleased to announce that its next-generation sequencing (NGS) based CFTR assay is now compliant under the European In Vitro Diagnostic Regulation... ► Artikel lesen | |
| 22.09. | Devyser Diagnostics AB: Bulletin from an Extraordinary General Meeting in Devyser Diagnostics AB (publ) held on 22 September 2025 | 94 | GlobeNewswire (Europe) | An Extraordinary General Meeting of Devyser Diagnostics AB (publ) ("Devyser" or the "Company") was held on Monday, 22 September 2025 at Bränningevägen 12, 120 54 Årsta. The main resolution passed at... ► Artikel lesen | |
| 15.08. | Devyser im zweiten Quartal 2025: Umsatz steigt um 27 % bei Rückkehr in die Gewinnzone | 1 | Investing.com Deutsch | ||
| 15.08. | Devyser Q2 2025 presentation: Revenue jumps 27% as profitability returns | 3 | Investing.com | ||
| 22.07. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period April to June 2025 | 161 | GlobeNewswire (Europe) | "A positive operating result was recorded in the second quarter. The effects of the cost-cutting program initiated at the beginning of the year can already be seen in both current costs and in the cost... ► Artikel lesen | |
| 30.06. | Devyser Diagnostics AB: Devyser launches Genomic Blood Typing assay: All blood groups, one simple test | 176 | GlobeNewswire (Europe) | Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation sequencing (NGS)-based solution that redefines molecular blood group research. Developed exclusively, this... ► Artikel lesen | |
| 29.04. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period January to March 2025 | 391 | GlobeNewswire (Europe) | "A quarter has passed since I took over as acting CEO and it has been an eventful first few months. Despite the turbulent environment, marked by geopolitical uncertainty, we are able to report our second... ► Artikel lesen | |
| 14.04. | Devyser Diagnostics AB: Jan Wahlström new CEO for Devyser | 257 | GlobeNewswire (Europe) | Devyser's board has appointed Jan Wahlström as new CEO, effective August 4.Jan Wahlström has a long background in leading and developing companies in the Health Care and Life Science areas internationally.... ► Artikel lesen | |
| 19.02. | Devyser Diagnostics AB: Devyser secures a major SEK 16.8M tender in Italy with 30% growth | 257 | GlobeNewswire (Europe) | Devyser a leading provider of genetic testing solutions, has been awarded a significant tender for the supply of its comprehensive next-generation sequencing (NGS) tests for critical genetic markers.... ► Artikel lesen | |
| 13.02. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes year-end report for January to December 2024 | 393 | GlobeNewswire (Europe) | "Net sales increased during the fourth quarter by 41.5 percent to SEK 64.2 million, compared with the corresponding quarter of 2023. The growth and strong performance are a result of robust development... ► Artikel lesen | |
| 28.01. | Devyser Diagnostics AB: Devyser wins tender in Italy for its cystic fibrosis NGS test worth up to 5.4 million SEK | 209 | GlobeNewswire (Europe) | Devyser has secured a tender for its cystic fibrosis NGS test, Devyser CFTR. The tender with Policlinico di Bari is valid for five years with an estimated total order value up to 5.4 million SEK
"This... ► Artikel lesen | |
| 16.01. | Devyser Diagnostics AB: Devyser publishes preliminary result for Q4 2024 | 732 | GlobeNewswire (Europe) | In light of this morning's communication that Fredrik Alpsten is leaving his position as CEO of Devyser and to avoid speculation, Devyser is releasing a summary of the year-end report for 2024 before... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDTRONIC | 78,52 | -0,32 % | Medtronic: From Curse to Career | Cardiac mapper turned treatment of his own heart condition into a new career NORTHAMPTON, MA / ACCESS Newswire / November 3, 2025 / David Stalls thought the dangerous heart rhythm problem that plagued... ► Artikel lesen | |
| HCA HEALTHCARE | 410,80 | +0,02 % | HCA Healthcare, Inc. - 8-K, Current Report | ||
| LANTHEUS | 49,780 | -0,96 % | Lantheus Gets FDA PDUFA Date For LNTH-2501 Diagnostic Kit In March | ||
| ENVISTA | 17,400 | -1,14 % | Envista Holdings Corporation: Envista Reports Third Quarter 2025 Results | BREA, Calif., Oct. 29, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended September 26, 2025."This was another strong quarter... ► Artikel lesen | |
| CAREDX | 13,045 | +3,24 % | CareDx, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| SYNEOS HEALTH | - | - | Research Solutions, Inc.: Research Solutions Reports Fourth Quarter and Fiscal Year 2025 Results | Reports 36% YoY Platform Revenue Increase, ARR of $20.9 Million and Record Fiscal Year Net Income and Adjusted EBITDA
HENDERSON, Nev., Sept. 18, 2025 /PRNewswire/... ► Artikel lesen | |
| GT BIOPHARMA | 0,535 | 0,00 % | GT Biopharma, Inc.: GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies | The Company is well on track with Phase 1 enrollment now that both patients in Cohort 3 have successfully initiated treatment with no evidence of dose-limiting toxicities or tolerability concerns... ► Artikel lesen | |
| CARMAT | 0,099 | -100,00 % | CARMAT Provides an Update on the Ongoing Receivership Procedure | A takeover bid within the context of a sales plan has been received by the judiciary administrator
Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced... ► Artikel lesen | |
| CHEMOMETEC | 103,20 | +1,78 % | Chemometec A/S: Upgrade of guidance | ANNOUNCEMENT NO. 295 28 October 2025 Upgrade of guidance ChemoMetec experiences an increased interest in its technology, not the least the XcytoMatic platform, and consequently expects a positive... ► Artikel lesen | |
| POLAREAN IMAGING | 0,001 | 0,00 % | Polarean shares plunge as board launches strategic review | ||
| ARRAIL GROUP | 0,212 | 0,00 % | ARRAIL GROUP (06639): POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON SEPTEMBER 26, 2025 | ||
| FRESENIUS MEDICAL CARE | 41,170 | -9,85 % | Fresenius Medical Care AG: Solide Q3-Ergebnisse mit stabilen Margen; HALTEN. | Fresenius Medical Care (FME) hat im dritten Quartal 2025 solide Ergebnisse berichtet und somit seine Erholungskurve im Rahmen der laufenden Transformation bestätigt. Die Umsätze stiegen im Vergleich... ► Artikel lesen | |
| FRESENIUS | 48,520 | -1,52 % | AKTIE IM FOKUS 2: FMC fallen - Erwartung möglicher Platzierung durch Fresenius | (Neu: Weitere Details) FRANKFURT (dpa-AFX Broker) - Die Aktien von Fresenius Medical Care (FMC) sind am Dienstag trotz einer überraschend positiven Geschäftsentwicklung im dritten Quartal unter Druck... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 49,250 | +0,88 % | dpa-AFX-Überblick: UNTERNEHMEN vom 29.10.2025 - 15.15 Uhr | ROUNDUP 2/Nach Gewinneinbruch: Warum es bei Mercedes nicht läuft STUTTGART - Beim Autobauer Mercedes -Benz läuft es gerade alles andere als rund. Der Überschuss ging in den ersten neun Monaten um... ► Artikel lesen |
Das Unternehmen DEVYSER DIAGNOSTICS AB kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 11,120 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DEVYSER DIAGNOSTICS AB finden Sie auf Wallstreet Online.